ASCO 2022 | Zanubrutinib monotherapy in R/R indolent NHL
Tycel Phillips
• 5 Jun 2022
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, describes the safety and efficacy results from a Phase I/II, open-label, multicenter, single-agent study of the Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma. The results of this study suggest a favorable benefit-risk profile and support zanubrutinib as a potentially meaningful addition to available therapies for patients with R/R marginal zone lymphoma (MZL) and follicular lymphoma (FL). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
